Horner has more than 40 years of industry experience gained with biotech and big pharma companies. He was most recently ceo of Prestwick Pharmaceuticals, a private CNS company that was sold to Biovail Corporation and Ovation Pharmaceuticals in 2008.
Prior to joining Prestwick, Horner was ceo of Vicuron, a publicly listed anti-infectives company that was sold to Pfizer for US$1.9bn in 2005. He also worked for Ligand Pharmaceuticals following a career at Abbott Laboratories where rose to president of the company’s business in Canada.
‘I have been attracted to this opportunity by the company’s rich pipeline of clinical and pre-clinical drug candidates focused on dermatological indications, its deep understanding of the science behind a number of serious skin disorders, as well as its technology platform with broad utility. I am sure that from this strong base we will be able to generate significant value for Creabilis shareholders,’ said Horner.
Dermatology specialist appoints chairman
George Horner joins Creabilis of Luxembourg
You may also like
Packaging
How pharma packaging manufacturers role is evolving: the case of extractables testing
As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Packaging
Dual-chamber packaging systems as a simplification factor in the supply chain
Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma